These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 22345656)

  • 1. IL28B polymorphisms do not predict response to therapy in chronic hepatitis C with HCV genotype 5.
    Antaki N; Bibert S; Kebbewar K; Asaad F; Baroudi O; Alideeb S; Hadad M; Abboud D; Sabah H; Bochud PY; Negro F
    Gut; 2012 Nov; 61(11):1640-1. PubMed ID: 22345656
    [No Abstract]   [Full Text] [Related]  

  • 2. Enhancing predictive ability of IL28B-SNPs for SVR in HCV.
    Amanzada A; Schneider S; Moriconi F; Mihm S; van Thiel DH; Ramadori G
    Aliment Pharmacol Ther; 2012 Jan; 35(2):317-8. PubMed ID: 22172087
    [No Abstract]   [Full Text] [Related]  

  • 3. IL28B rs12979860 C/T polymorphism in elderly chronic hepatitis C patients treated with pegylated-interferon and ribavirin.
    Giannini EG; Marenco S; Baldissarro I; Fazio V
    Aliment Pharmacol Ther; 2011 Aug; 34(3):398-400. PubMed ID: 21726252
    [No Abstract]   [Full Text] [Related]  

  • 4. Association between IL28B polymorphism and treatment response in patients with genotype 4 chronic hepatitis C.
    Stättermayer AF; Hofer H; Ferenci P
    J Hepatol; 2012 Sep; 57(3):706; author reply 706-7. PubMed ID: 22748774
    [No Abstract]   [Full Text] [Related]  

  • 5. Reply to: "Understanding triphasic HCV decline during treatment in the era of IL28B polymorphisms and direct acting antiviral agents via mathematical modeling".
    Howell CD; Jin R; Dowling TC
    J Hepatol; 2013 Apr; 58(4):842-3. PubMed ID: 23246702
    [No Abstract]   [Full Text] [Related]  

  • 6. Introduction to the genetics and biology of interleukin-28B.
    Urban T; Charlton MR; Goldstein DB
    Hepatology; 2012 Jul; 56(1):361-6. PubMed ID: 22511448
    [No Abstract]   [Full Text] [Related]  

  • 7. Limitations of retrospective IL28B polymorphisms and IP-10 real life studies in hepatitis C.
    Hadziyannis SJ
    Aliment Pharmacol Ther; 2011 Jul; 34(1):102-3. PubMed ID: 21631552
    [No Abstract]   [Full Text] [Related]  

  • 8. Understanding triphasic HCV decline during treatment in the era of IL28B polymorphisms and direct acting antiviral agents via mathematical modeling.
    Dahari H; Cotler SJ; Layden TJ; Perelson AS
    J Hepatol; 2013 Apr; 58(4):840-2. PubMed ID: 23246507
    [No Abstract]   [Full Text] [Related]  

  • 9. Is hepatitis C subtyping still relevant in the era of direct-acting antiviral therapy?
    Eslam M; George J
    Hepatol Int; 2015 Jan; 9(1):5-8. PubMed ID: 25788373
    [No Abstract]   [Full Text] [Related]  

  • 10. Lost in translation? IL28B's discovery and the journey back to the patient.
    Clark PJ; Muir AJ
    Hepatology; 2012 Jul; 56(1):5-8. PubMed ID: 22511499
    [No Abstract]   [Full Text] [Related]  

  • 11. Genetic variation in IL28B: impact on drug development for chronic hepatitis C infection.
    Clark PJ; Thompson AJ; McHutchison JG
    Clin Pharmacol Ther; 2010 Nov; 88(5):708-11. PubMed ID: 20881951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic variant links hepatitis C virus clearance and treatment response.
    McBride D
    ONS Connect; 2013 Mar; 28(1):50. PubMed ID: 23495532
    [No Abstract]   [Full Text] [Related]  

  • 13. Commentary: the ss469415590 SNP--an IL28B marker looking for a home.
    Congly SE; Lee SS
    Aliment Pharmacol Ther; 2014 Feb; 39(3):339. PubMed ID: 24397320
    [No Abstract]   [Full Text] [Related]  

  • 14. Is there need for more than one IL28B single nucleotide polymorphism in hepatitis C clinical practice?
    Galmozzi E; De Nicola S; Aghemo A; Colombo M
    Hepatology; 2013 Jan; 57(1):416. PubMed ID: 22745042
    [No Abstract]   [Full Text] [Related]  

  • 15. The importance of IL28B genotype in hepatitis C virus-associated liver transplantation.
    Lange CM
    Liver Int; 2013 Feb; 33(2):169-71. PubMed ID: 23295049
    [No Abstract]   [Full Text] [Related]  

  • 16. [The time factor in the management of chronic hepatitis C].
    Serra MA
    Rev Esp Enferm Dig; 2008 Apr; 100(4):230-5. PubMed ID: 18563981
    [No Abstract]   [Full Text] [Related]  

  • 17. HCV infection and miravirsen.
    Sanchez-Niño MD; Ortiz A
    N Engl J Med; 2013 Aug; 369(9):877-8. PubMed ID: 23984740
    [No Abstract]   [Full Text] [Related]  

  • 18. HCV infection and miravirsen.
    Janssen HL; Kauppinen S; Hodges MR
    N Engl J Med; 2013 Aug; 369(9):878. PubMed ID: 23984739
    [No Abstract]   [Full Text] [Related]  

  • 19. Hepatitis C virus infection: when is a cure not a cure?
    Tillmann HL
    J Infect Dis; 2014 Jan; 209(1):6-8. PubMed ID: 24127562
    [No Abstract]   [Full Text] [Related]  

  • 20. Antisense therapy for hepatitis C virus infection.
    de Jong YP; Jacobson IM
    J Hepatol; 2014 Jan; 60(1):227-8. PubMed ID: 24036232
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.